12,372 trials
Chemotherapy-induced Nausea and Vomiting
Primary: Number of Participants With Treatment-emergent AEs at Cycle 1 — 121; 122 Participants
Opiate Dependence
Primary: Relapse to Opioid Use in Subjects by Month 3 — 16; 20 Participants — p=0.38
Hemorrhage
Primary: Number of Participants With Drug-related Adverse Events (AEs) — 0 Participants
Cataract · Pain · Ocular Inflammation
Primary: Number of Participants With Complete Resolution of Anterior Chamber (AC) Cells at Visit 5 (Postoperative Day 8) — 40; 52; 61 Participants
Influenza
Primary: Number and Percentage of Seroconverted Participants at 21 Days Post-vaccination — 413; 216; 411; 201 Participants
Constipation Predominant Irritable Bowel Syndrome
Primary: Percentage of Subjects With Overall Response for 6 Out of 12 Weeks — 107; 71 Participants — p=<0.001
Post-Menopausal Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine BMD at Month 6 — 9.2; 9.0 percent change — p=0.84
Influenza · Influenza Vaccines
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease — 5.6; 5.5; 5.6; 5.4 Titers
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c — -1.5; -1.8; -1.0; -1.5 Percentage of glycosylated haemoglobin — p=<.0001
Post-operative Dental Pain
Primary: Time to Confirmed Perceptible Pain Relief — NA; 18.7; 23.5; 28.1 Minutes
Hyperlipidemias
Primary: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) — -36.2; -17.2; -23.2; 1.8 Percent Change — p=<0.001
Rheumatoid Arthritis
Primary: Area Under the Concentration-time Curve (AUCτ) of Infliximab at Steady State (Part 1) — 12032957.5; 5047724.2; 7333767.0; 9930696.6 hr*ng/mL
Urological Manifestations
Primary: Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product and do Not…
Bacterial Infection · Benign Neoplasm · Malignant Neoplasm
Primary: Central Line-associated Bloodstream Infections (CLABSI) Events During the At-risk Days — 5.44; 3.1 CLABSI per 1000 at-risk days.
Post Menopausal Breast Cancer
Primary: Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades — 4; 0; 4; 195 Participants